Max Healthcare pushes Gurgaon project to end-FY27
Management cuts its oncology revenue outlook and hits project delays, even as brownfield expansions hold steady.
— 3 earlier stories on Max Healthcare Institute Ltd. →What's new
- Gurgaon greenfield commissioning slips from H1 FY27 to end-FY27.
- Oncology revenue share guidance cut to 21-22% due to CGHS drug pricing changes.
- Lucknow hospital expansion faces further delays.
Why it matters
The oncology segment is a core revenue driver, and the impact from regulatory pricing changes is now permanent. When greenfield projects start slipping beyond initial estimates, return-on-capital timelines lengthen. The market must reconcile the promised capacity rollout with a shifting revenue mix and slower project delivery.
What we're watching
- Whether the Lucknow project hits further setbacks in the next quarter.
- The impact of CGHS pricing on margins beyond just revenue mix.
- Execution speed on the 20% network-wide brownfield capacity additions.
The full read
Max Healthcare is recalibrating its growth engine. Management informed analysts that the 500-bed Gurgaon greenfield facility will miss its H1 FY27 target, slipping to the end of the fiscal year. The ₹1,400 crore Lucknow greenfield project faces similar delays. These structural drags on capacity expansion come alongside a lower outlook for oncology revenue. A pivot in CGHS drug pricing has forced management to reset its expected oncology mix to 21-22%, down from the previous 25-26% guidance. Brownfield additions across existing facilities remain the sole bright spot, keeping the 20% capacity increase target intact. The company faces a dual test: finishing its greenfield pipeline despite the delays, while absorbing the lower revenue contribution from a key therapeutic area. For now, the operational narrative is moving away from the aggressive growth schedule investors were expecting.